Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0001511 (Adhesion)
 5,955 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sonohysterography (SHG) may replace hysteroscopy as the standard method to evaluate intrauterine filling defects noted on hysterosalpingography (HSG). Twenty-six patients with evidence of intrauterine filling defects on HSG underwent SHG in the office with transvaginal ultrasonography before diagnostic or operative hysteroscopy. Polyps were identified in 11 women by SHG and were confirmed by hysteroscopy and histology. Adhesions seen on SHG in four women were also confirmed by hysteroscopy. Thus SHG not only correctly identified myomas in all six patients, but helped determine which ones could be resected by hysteroscopy and which might benefit from preoperative gonadotropin-releasing hormone analog treatment. Five patients with intrauterine filling defects on HSG were subsequently shown to have normal endometrial cavities at SHG and hysteroscopy. We believe SHG is a useful technique for evaluating patients with abnormal HSGs, reducing the requirement for more expensive and invasive diagnostic hysteroscopy. In addition, it provides more thorough assessment before operative hysteroscopy.
 ...
PMID:Sonohysterography to Evaluate Uterine Defects on Hysterosalpingography and Its Correlation with Hysteroscopy 907 27

In Jamaica, uterine fibroids are the most common reason for major surgery in hospital gynecology wards. No treatment is needed in asymptomatic women with small fibroids (less than 12-week size). When fibroids are symptomatic, however, they need to be treated. Medical therapy alone (e.g., gonadotropin-releasing hormone agonists) has produced disappointing results. Myomectomy by laparotomy is the method of choice in most women. Adhesion formation can be reduced by careful operative technique, limited number of incisions, and use of an Interceed barrier to prevent contact between damaged tissue. However, a recurrence rate of 27% has been reported after 10 years, necessitating reoperation. Hysterectomy is recommended in women who have completed childbearing. Depo-Provera has been used to reduce the menorrhagia associated with uterine fibroids, but its effect is temporary and there is no impact on the size and growth of the fibroids.
 ...
PMID:An update on the management of uterine fibroids. 1229 47

Adhesion formation is of major concern to the pelvic surgeon. Most patients develop postoperative adhesions regardless of whether the mode of access to the abdominal cavity is by laparoscopy or laparotomy. Infertility is related to adhesions in the pelvis in 15-20% of cases. Peritoneal adhesions are the main cause of mechanical bowel obstruction in 65-80% of cases and contribute to a large extent to health-care expenditures. To prevent the formation of postoperative adhesions, a variety of medications have been studied such as glucocorticoids, heparin, dextran 70, saline solution, antibiotics, promethazine, antihistamines, prostaglandin synthesis inhibitors, Ringer's lactate solution, calcium-channel blockers and barriers such as Interseed and Gore-Tex. Such adhesions can be induced when operating on myomas and endometriosis. Experimental and clinical studies have demonstrated various mechanisms of action to be involved in adhesion prevention when gonadotropin-releasing hormone agonists (GnRH-a) are used for treatment. The following have been demonstrated and suggested: (1) Hypoestrogenic condition was found in rats to be associated with decreased adhesion formation. This could be related to the influence on estrogen-dependent growth factors and growth modulators by reliable and constant inhibition of ovarian estradiol biosynthesis and secretion, but also non-competitive estrogen antagonism seems to play a role. (2) Treatment with GnRH-a reduces the growth hormone release stimulated by growth hormone-releasing hormone. (3) GnRH-a treatment influences neoangiogenesis by affecting vascular endothelial growth factor and basic fibroblastic growth factor. (4) GnRH-a reduce the basal rate of coagulatory processes. The frequency and extent of fibrin-generating and degrading processes are reduced. Activity of the plasminogen activating inhibitor is reduced, suggesting an improvement infibrinolytic reactivity. (5) GnRH-a use alters the vascular resistance index, pulsatility index and vascular peak velocity, and possible immune response. (6) Avoidance of bleeding can reduce fibrin and therefore decreases the matrix for invasion by fibroblasts. (7) GnRH-a reduce the degree of inflammation postoperatively. Adhesion prevention seems to be at its best when pre- and postoperative GnRH-a treatment is administered. At present, there are trends to operate without prior treatment with GnRH-a. Based upon the data available, it seems worthwhile to consider preoperative and also postoperative treatment with GnRH-a: pretreatment for at least 2-3 months seems to be indicated, and a similar time after operation, to block the events associated with adhesion formation.
 ...
PMID:Gonadotropin-releasing hormone agonists for prevention of postoperative adhesions: an overview. 1562 74

This paper presents the results of an experimental study of the adhesion forces between components of model conjugated magnetite nanoparticle systems for improved selectivity in the specific targeting of triple negative breast cancer. Adhesion forces between chemically synthesized magnetite nanoparticles (CMNPs), biosynthesized magnetite nanoparticles (BMNPs), as well as their conjugated systems and triple negative breast cancer cells (MDA-MB-231) or normal breast cells (MCF 10A) are elucidated at a nanoscale. In all cases, the BMNPs had higher adhesion forces (to breast cancer cells and normal breast cells) than CMNPs. The adhesion of LHRH-conjugated BMNPs or BSA-conjugated BMNPs to cancer cells is shown to be about 6 times to that of normal breast cells. The increase in adhesion forces between luteinizing hormone-releasing hormone, LHRH- or EphA2, a breast specific antibody(BSA)-conjugated BMNPs to breast cancer cells is attributed to van der Waals interactions between the peptides/antibodies from the conjugated nanoparticles and the over-expressed receptors (revealed using immunofluorescence staining) on the surfaces of the breast cancer. The implications of the results are discussed for the selectivity and specificity of breast cancer targeting by ligand-conjugated BMNPs.
 ...
PMID:Adhesion of ligand-conjugated biosynthesized magnetite nanoparticles to triple negative breast cancer cells. 2822 10